| Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma RJ Motzer, K Penkov, J Haanen, B Rini, L Albiges, MT Campbell, ... New England Journal of Medicine 380 (12), 1103-1115, 2019 | 2462 | 2019 |
| Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... New England Journal of Medicine 383 (13), 1218-1230, 2020 | 1261 | 2020 |
| Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma TK Choueiri, RJ Motzer, BI Rini, J Haanen, MT Campbell, B Venugopal, ... Annals of Oncology 31 (8), 1030-1039, 2020 | 448 | 2020 |
| Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial RJ Motzer, PB Robbins, T Powles, L Albiges, JB Haanen, J Larkin, XJ Mu, ... Nature medicine 26 (11), 1733-1741, 2020 | 406 | 2020 |
| Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding … TK Choueiri, J Larkin, M Oya, F Thistlethwaite, M Martignoni, P Nathan, ... The lancet oncology 19 (4), 451-460, 2018 | 283 | 2018 |
| Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer R Koster, A Di Pietro, H Timmer-Bosscha, JH Gibcus, A Van Den Berg, ... The Journal of clinical investigation 120 (10), 3594-3605, 2010 | 248 | 2010 |
| Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis S Gandini, S Iodice, E Koomen, A Di Pietro, F Sera, S Caini European journal of cancer 47 (17), 2607-2617, 2011 | 156 | 2011 |
| COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma R Dummer, KT Flaherty, C Robert, A Arance, JWB de Groot, C Garbe, ... Journal of Clinical Oncology 40 (36), 4178-4188, 2022 | 151 | 2022 |
| Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach A Testori, G Tosti, C Martinoli, G Spadola, F Cataldo, F Verrecchia, ... Dermatologic therapy 23 (6), 651-661, 2010 | 147 | 2010 |
| Clinical evaluation of M30 and M65 ELISA cell death assays as circulating biomarkers in a drug-sensitive tumor, testicular cancer EC de Haas, A di Pietro, KL Simpson, C Meijer, AJH Suurmeijer, ... Neoplasia 10 (10), 1041-1048, 2008 | 115 | 2008 |
| Maintenance avelumab+ best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 … T Powles, SH Park, E Voog, C Caserta, BP Valderrama, H Gurney, ... Journal of Clinical Oncology 38 (18_suppl), LBA1-LBA1, 2020 | 114 | 2020 |
| Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after≥ 2 years of follow-up T Powles, SH Park, C Caserta, BP Valderrama, H Gurney, A Ullén, ... Journal of Clinical Oncology 41 (19), 3486-3492, 2023 | 102 | 2023 |
| Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial T Powles, SS Sridhar, Y Loriot, J Bellmunt, XJ Mu, KA Ching, J Pu, ... Nature Medicine 27 (12), 2200-2211, 2021 | 99 | 2021 |
| Biomarker analyses from JAVELIN Renal 101: Avelumab+ axitinib (A+ Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC). TK Choueiri, L Albiges, JBAG Haanen, JMG Larkin, M Uemura, SK Pal, ... Journal of Clinical Oncology 37 (15_suppl), 101-101, 2019 | 96 | 2019 |
| Testicular germ cell tumours: the paradigm of chemo-sensitive solid tumours A di Pietro, EGE de Vries, JA Gietema, DCJ Spierings, S de Jong The international journal of biochemistry & cell biology 37 (12), 2437-2456, 2005 | 77 | 2005 |
| JAVELIN Renal 101: A randomized, phase III study of avelumab+ axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC) RJ Motzer, K Penkov, J Haanen, BI Rini, L Albiges, MT Campbell, ... Annals of Oncology 29, viii724, 2018 | 54 | 2018 |
| First-line avelumab+ axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. TK Choueiri, JMG Larkin, M Oya, FC Thistlethwaite, M Martignoni, ... Journal of Clinical Oncology 35 (15_suppl), 4504-4504, 2017 | 54 | 2017 |
| Pro-and anti-apoptotic effects of p53 in cisplatin-treated human testicular cancer are cell context-dependent A di Pietro, R Koster, W Boersma-van Eck, WA Dam, NH Mulder, ... Cell Cycle 11 (24), 4552-4562, 2012 | 53 | 2012 |
| Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial TK Choueiri, J Larkin, S Pal, RJ Motzer, BI Rini, B Venugopal, B Alekseev, ... ESMO open 6 (3), 100101, 2021 | 49 | 2021 |
| Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101 M Uemura, Y Tomita, H Miyake, S Hatakeyama, H Kanayama, ... Cancer science 111 (3), 907-923, 2020 | 43 | 2020 |
